---
title: "MetaVia Inc. (MTVA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/MTVA.US.md"
symbol: "MTVA.US"
name: "MetaVia Inc."
industry: "Biotechnology"
---

# MetaVia Inc. (MTVA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.metaviatx.com](https://www.metaviatx.com) |

## Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinica...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.30 | 115/606 | - | - | - |
| PB | 0.77 | 63/606 | 3.01 | 2.41 | 1.00 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-21T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 50% |
| Overweight | 1 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.51 |
| Highest Target | 209.00 |
| Lowest Target | 40.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/MTVA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/MTVA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/MTVA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.